In Q3 2023,
Summary | Q3 23 | Q3 22 | YTD 2023 | YTD 2022 | 2022 |
DKK thousands | |||||
Net Revenue | - | - | - | - | - |
Operating result | -10,862 | -8,416 | -31,164 | -21,358 | -32,461 |
Net result | -9,314 | -7,041 | -25,990 | -16,743 | -27,340 |
Cash and bank | 8,945 | 31,700 | 8,945 | 31,700 | 26,013 |
Result per share (DKK) *) | -0.78 | -0.60 | -2.19 | -1.43 | -2.33 |
Solidity (%) **) | 73% | 91% | 73% | 91% | 90% |
*) Result per share (DKK per share): Operating result divided by the average number of shares during the period.
**) Solidity: Total equity divided by total capital and liability.
HIGHLIGHTS DURING Q2:
- Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the
World Molecular Imaging Congress inPrague - Further positive interim data from phase lla trial of FG001 in head & neck cancer
- Completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer
- Completes a Directed Share Issue raising
SEK 15 million - Issues warrants to Board members, management, and employees, as well as the investors participating in the Directed Share Issue
HIGHLIGHTS AFTER Q2
- Receives FDA Orphan Drug Designation for FG001 in high-grade glioma
- Confirms positive topline results from phase lla trial of FG001 in head & neck cancer at IAOO
- Announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer
For further information, please contact:
+45 24 25 62 66,
ma@fluoguide.com
About
The Company has published key results on the efficacy of FG001 as well as showing it was well tolerated and safe from clinical trials in patients with aggressive brain cancer (high-grade glioma) that undergo surgery. In addition,
For more information on the Company, please visit www.fluoguide.com
© Modular Finance, source